Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ASP3082 + Cetuximab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ASP3082 | ASP 3082|ASP-3082 | KRAS G12D Inhibitor 16 | ASP3082 degrades KRAS G12D, potentially leading to decreased Erk phosphorylation and inhibition of cell growth and tumor regression (European Journal of Cancer 174 (2022): S30). | |
Cetuximab | Erbitux | IMC-C225 | EGFR Antibody 60 | Erbitux (cetuximab) is a monoclonal antibody directed against EGFR, which inhibits signal transduction and cell proliferation (PMID: 28695301). Erbitux (cetuximab) is FDA approved for use in head and neck squamous cell carcinoma and KRAS wild-type, EGFR positive colorectal cancer (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05382559 | Phase I | ASP3082 ASP3082 + Cetuximab | A Study of ASP3082 in Adults With Previously Treated Solid Tumors | Recruiting | USA | FRA | ESP | 2 |